Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

8Y22

FGFR1 kinase domain with a covalent inhibitor 9g

This is a non-PDB format compatible entry.
Summary for 8Y22
Entry DOI10.2210/pdb8y22/pdb
DescriptorFibroblast growth factor receptor 1, ~{N}-[4-[[4-azanyl-3-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]phenyl]propanamide, SULFATE ION, ... (4 entities in total)
Functional Keywordsfibroblast growth factor receptor 1, transferase
Biological sourceHomo sapiens (human)
Total number of polymer chains2
Total formula weight71838.27
Authors
Chen, X.J.,Chen, Y.H. (deposition date: 2024-01-25, release date: 2024-06-26, Last modification date: 2024-10-30)
Primary citationDeng, W.,Chen, X.,Liang, H.,Song, X.,Xiang, S.,Guo, J.,Tu, Z.,Zhou, Y.,Chen, Y.,Lu, X.
Design, synthesis and biological evaluation of 5-amino-1H-pyrazole-4-carboxamide derivatives as pan-FGFR covalent inhibitors.
Eur.J.Med.Chem., 275:116558-116558, 2024
Cited by
PubMed Abstract: The aberrant activation of FGFRs plays a critical role in various cancers, leading to the development of several FGFR inhibitors in clinic. However, the emergence of drug resistance, primarily due to gatekeeper mutations in FGFRs, has limited their clinical efficacy. To address the unmet medical need, a series of 5-amino-1H-pyrazole-4-carboxamide derivatives were designed and synthesized as novel pan-FGFR covalent inhibitors targeting both wild-type and the gatekeeper mutants. The representative compound 10h demonstrated nanomolar activities against FGFR1, FGFR2, FGFR3 and FGFR2 V564F gatekeeper mutant in biochemical assays (IC = 46, 41, 99, and 62 nM). Moreover, 10h also strongly suppressed the proliferation of NCI-H520 lung cancer cells, SNU-16 and KATO III gastric cancer cells with IC values of 19, 59, and 73 nM, respectively. Further X-ray co-crystal structure revealed that 10h irreversibly binds to FGFR1. The study provides a new promising point for anticancer drug development medicated by FGFRs.
PubMed: 38870833
DOI: 10.1016/j.ejmech.2024.116558
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.792 Å)
Structure validation

236620

PDB entries from 2025-05-28

PDB statisticsPDBj update infoContact PDBjnumon